Anti-cancer natural products isolated from chinese medicinal herbs

Chinese Medicine

Volumn 6, Issue , 2011, Pages

  Tan, Wen ^a,b   Lu, Jinjian ^a,b,c   Huang, Mingqing ^a,b,d   Li, Yingbo ^a,b   Chen, Meiwan ^a,b   Wu, Guosheng ^a,b   Gong, Jian ^a,b   Zhong, Zhangfeng ^a,b   Xu, Zengtao ^a,b   Dang, Yuanye ^a,b   Guo, Jiajie ^a,b   Chen, Xiuping ^a,b   Wang, Yitao ^a,b  

^a UNIVERSITY OF MACAU   (Macao)

^b University of Macau   (Macao)

^c ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^d FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID DERIVATIVE; ANTINEOPLASTIC AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; BERBERINE; BETA ELEMENE; CHINESE DRUG; CURCUMIN; EMODIN; FLAVONOID; GAMBOGIC ACID; GINSENOSIDE RG 3; HERBACEOUS AGENT; NATURAL PRODUCT; ORIDONIN; QUINONE DERIVATIVE; SAPONIN DERIVATIVE; SHIKONIN; SILIBININ; TERPENE DERIVATIVE; TRIPTOLIDE; URSOLIC ACID; WOGONIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CHINESE HERB; DRUG ISOLATION; DRUG RESEARCH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; NONHUMAN; REVIEW;

EID: 79960555687     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/1749-8546-6-27     Document Type: Review

References (236)

1. Bell RM. A review of complementary and alternative medicine practices among cancer survivors. Clin J Oncol Nurs 2010, 14:365-370. 10.1188/10.CJON.365-370, 20529798.
2. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003, 66:1022-1037. 10.1021/np030096l, 12880330.
3. Panthong A, Norkaew P, Kanjanapothi D, Taesotikul T, Anantachoke N, Reutrakul V. Anti-inflammatory, analgesic and antipyretic activities of the extract of gamboge from Garcinia hanburyi Hook f. J Ethnopharmacol 2007, 111:335-340. 10.1016/j.jep.2006.11.038, 17360136.
4. Kasibhatla S, Jessen KA, Maliartchouk S, Wang JY, English NM, Drewe J, Qiu L, Archer SP, Ponce AE, Sirisoma N, Jiang S, Zhang HZ, Gehlsen KR, Cai SX, Green DR, Tseng B. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci USA 2005, 102:12095-12100. 10.1073/pnas.0406731102, 1189297, 16103367.
5. Gu H, Wang X, Rao S, Wang J, Zhao J, Ren FL, Mu R, Yang Y, Qi Q, Liu W, Lu N, Ling H, You Q, Guo Q. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol Cancer Ther 2008, 7:3298-3305. 10.1158/1535-7163.MCT-08-0212, 18852133.
6. Wu ZQ, Guo QL, You QD, Zhao L, Gu HY. Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol Pharm Bull 2004, 27:1769-1774. 10.1248/bpb.27.1769, 15516720.
7. Qiang L, Yang Y, You QD, Ma YJ, Yang L, Nie FF, Gu HY, Zhao L, Lu N, Qi Q, Liu W, Wang XT, Guo QL. Inhibition of glioblastoma growth and angiogenesis by gambogic acid: an in vitro and in vivo study. Biochem Pharmacol 2008, 75:1083-1092. 10.1016/j.bcp.2007.10.033, 18070617.
8. Qi Q, Gu H, Yang Y, Lu N, Zhao J, Liu W, Ling H, You QD, Wang X, Guo Q. Involvement of matrix metalloproteinase 2 and 9 in gambogic acid induced suppression of MDA-MB-435 human breast carcinoma cell lung metastasis. J Mol Med 2008, 86:1367-1377. 10.1007/s00109-008-0398-z, 18777017.
9. Wang X, Chen Y, Han QB, Chan CY, Wang H, Liu Z, Cheng CH, Yew DT, Lin MC, He ML, Xu HX, Sung JJ, Kung HF. Proteomic identification of molecular targets of gambogic acid: role of stathmin in hepatocellular carcinoma. Proteomics 2009, 9:242-253. 10.1002/pmic.200800155, 19086098.
10. Rong JJ, Hu R, Qi Q, Gu HY, Zhao Q, Wang J, Mu R, You QD, Guo QL. Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53. Cancer Lett 2009, 284:102-112. 10.1016/j.canlet.2009.04.011, 19428175.
11. Zhai D, Jin C, Shiau CW, Kitada S, Satterthwait AC, Reed JC. Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther 2008, 7:1639-1646. 10.1158/1535-7163.MCT-07-2373, 2614397, 18566235.
12. Pandey MK, Sung B, Ahn KS, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB. Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 2007, 110:3517-3525. 10.1182/blood-2007-03-079616, 2077305, 17673602.
13. Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L, Zhang X, Ding J. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther 2007, 6:2429-2440. 10.1158/1535-7163.MCT-07-0147, 17876042.
14. Zhao J, Qi Q, Yang Y, Gu HY, Lu N, Liu W, Wang W, Qiang L, Zhang LB, You QD, Guo QL. Inhibition of alpha(4) integrin mediated adhesion was involved in the reduction of B16-F10 melanoma cells lung colonization in C57BL/6 mice treated with gambogic acid. Eur J Pharmacol 2008, 589:127-131. 10.1016/j.ejphar.2008.04.063, 18539272.
15. He D, Xu Q, Yan M, Zhang P, Zhou X, Zhang Z, Duan W, Zhong L, Ye D, Chen W. The NF-kappa B inhibitor, celastrol, could enhance the anti-cancer effect of gambogic acid on oral squamous cell carcinoma. BMC Cancer 2009, 9:343. 10.1186/1471-2407-9-343, 2760578, 19778460.
16. Wang J, Liu W, Zhao Q, Qi Q, Lu N, Yang Y, Nei FF, Rong JJ, You QD, Guo QL. Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology 2009, 256:135-140. 10.1016/j.tox.2008.11.014, 19084572.
17. Wang T, Wei J, Qian X, Ding Y, Yu L, Liu B. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett 2008, 262:214-222. 10.1016/j.canlet.2007.12.004, 18248784.
18. Chen B, Liang Y, Wu W, Cheng J, Xia G, Gao F, Ding J, Gao C, Shao Z, Li G, Chen W, Xu W, Sun X, Liu L, Li X, Wang X. Synergistic effect of magnetic nanoparticles of Fe(3)O(4) with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomedicine 2009, 4:251-259. 2789437, 20011242.
19. Minami M, Nishio K, Ajioka Y, Kyushima H, Shigeki K, Kinjo K, Yamada K, Nagai M, Satoh K, Sakurai Y. Identification of Curcuma plants and curcumin content level by DNA polymorphisms in the trnS-trnfM intergenic spacer in chloroplast DNA. J Nat Med 2009, 63:75-79. 10.1007/s11418-008-0283-7, 18688695.
20. Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008, 75:787-809. 10.1016/j.bcp.2007.08.016, 17900536.
21. Lopez-Lazaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 2008, 52(Suppl 1):S103-127.
22. Bhandarkar SS, Arbiser JL. Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol 2007, 595:185-195. 10.1007/978-0-387-46401-5_7, 17569211.
23. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?. AAPS J 2009, 11:495-510. 10.1208/s12248-009-9128-x, 2758121, 19590964.
24. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 2005, 11:7490-7498. 10.1158/1078-0432.CCR-05-1192, 16243823.
25. Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008, 57:1509-1517. 10.1136/gut.2008.152496, 2582343, 18596194.
26. Shinojima N, Yokoyama T, Kondo Y, Kondo S. Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumin- induced autophagy. Autophagy 2007, 3:635-637.
27. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 2007, 72:29-39. 10.1124/mol.106.033167, 17395690.
28. Jia YL, Li J, Qin ZH, Liang ZQ. Autophagic and apoptotic mechanisms of curcumin-induced death in K562 cells. J Asian Nat Prod Res 2009, 11:918-928. 10.1080/10286020903264077, 20183254.
29. Yoon MJ, Kim EH, Lim JH, Kwon TK, Choi KS. Superoxide anion and proteasomal dysfunction contribute to curcumin-induced paraptosis of malignant breast cancer cells. Free Radic Biol Med 2009, 48:713-726.
30. Nautiyal J, Banerjee S, Kanwar SS, Yu Y, Patel BB, Sarkar FH, Majumdar AP. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. Int J Cancer 2011, 128:951-961. 10.1002/ijc.25410, 20473900.
31. Ibrahim MA, Elbehairy AM, Ghoneim MA, Amer HA. Protective effect of curcumin and chlorophyllin against DNA mutation induced by cyclophosphamide or benzo[a]pyrene. Z Naturforsch C 2007, 62:215-222.
32. Arafa HM. Uroprotective effects of curcumin in cyclophosphamide -induced haemorrhagic cystitis paradigm. Basic Clin Pharmacol Toxicol 2009, 104:393-399. 10.1111/j.1742-7843.2009.00379.x, 19413659.
33. Venkatesan N, Chandrakasan G. Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant. Mol Cell Biochem 1995, 142:79-87. 10.1007/BF00928916, 7753045.
34. Siddique YH, Ara G, Beg T, Gupta J, Afzal M. Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and curcumin in cultured human blood lymphocytes. Exp Toxicol Pathol 2010, 62:503-508. 10.1016/j.etp.2009.06.010, 19608391.
35. Zhou QM, Zhang H, Lu YY, Wang XF, Su SB. Curcumin reduced the side effects of mitomycin C by inhibiting GRP58-mediated DNA cross-linking in MCF-7 breast cancer xenografts. Cancer Sci 2009, 100:2040-2045. 10.1111/j.1349-7006.2009.01297.x, 19703194.
36. Howells LM, Sale S, Sriramareddy SN, Irving GR, Jones DJ, Ottley CJ, Pearson DG, Mann CD, Manson MM, Berry DP, Gescher A, Steward WP, Brown K. Curcumin ameliorates oxaliplatin-induced chemoresistance in HCT116 colorectal cancer cells in vitro and in vivo. Int J Cancer 2010,
37. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer 2010, 62:919-930. 10.1080/01635581.2010.509835, 20924967.
38. Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M, Chauhan SC. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res 2010, 3:11. 10.1186/1757-2215-3-11, 2880315, 20429876.
39. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008, 65:1631-1652. 10.1007/s00018-008-7452-4, 18324353.
40. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C, Chollet P. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 2009, 9:8-14.
41. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, Aggarwal BB. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011, 68:157-164. 10.1007/s00280-010-1470-2, 20859741.
42. Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008, 14:4491-4499. 10.1158/1078-0432.CCR-08-0024, 18628464.
43. Li C, Zhou L, Lin G, Zuo Z. Contents of major bioactive flavones in proprietary traditional Chinese medicine products and reference herb of radix Scutellariae. J Pharm Biomed Anal 2009, 50:298-306. 10.1016/j.jpba.2009.04.028, 19481403.
44. Baumann S, Fas SC, Giaisi M, Müller WW, Merling A, Gülow K, Edler L, Krammer PH, Li-Weber M. Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCγ1- and Ca2+ -dependent apoptosis. Blood 2008, 111:2354-2363. 10.1182/blood-2007-06-096198, 18070986.
45. Yu JQ, Liu HB, Tian DZ, Liu YW, Lei JC, Zou GL. Changes in mitochondrial membrane potential and reactive oxygen species during wogonin-induced cell death in human hepatoma cells. Hepatol Res 2007, 37:68-76. 10.1111/j.1872-034X.2007.00003.x, 17300700.
46. Himeji M, Ohtsuki T, Fukazawa H, Tanaka M, Yazaki S, Ui S, Nishio K, Yamamoto H, Tasaka K, Mimura A. Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell. Cancer Lett 2007, 245:269-274. 10.1016/j.canlet.2006.01.011, 16497434.
47. Lee D-H, Kim C, Zhang L, Lee YJ. Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochem Pharmacol 2008, 75:2020-2033. 10.1016/j.bcp.2008.02.023, 2424318, 18377871.
48. Yang L, Zhang HW, Hu R, Yang Y, Qi Q, Lu N, Liu W, Chu YY, You QD, Guo QL. Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells. Biochem Cell Biol 2009, 87:933-942. 10.1139/O09-060, 19935879.
49. Lu N, Gao Y, Ling Y, Chen Y, Yang Y, Gu H-Y, Qi Q, Liu W, Wang X-T, You Q-D, Guo Q-L. Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2. Life Sci 2008, 82:956-963. 10.1016/j.lfs.2008.02.013, 18378261.
50. Lee E, Enomoto R, Koshiba C, Hirano H. Inhibition of P-glycoprotein by wogonin is involved with the potentiation of etoposide-induced apoptosis in cancer cells. Ann N Y Acad Sci 2009, 1171:132-136. 10.1111/j.1749-6632.2009.04722.x, 19723047.
51. Lee E, Enomoto R, Suzuki C, Ohno M, Ohashi T, Miyauchi A, Tanimoto E, Maeda K, Hirano H, Yokoi T, Sugahara C. Wogonin, a plant flavone, potentiates etoposide-induced apoptosis in cancer cells. Ann N Y Acad Sci 2007, 1095:521-526. 10.1196/annals.1397.056, 17404065.
52. Enomoto R, Koshiba C, Suzuki C, Lee E. Wogonin potentiates the antitumor action of etoposide and ameliorates its adverse effects. Cancer Chemother Pharmacol 2011, 67:1063-1072. 10.1007/s00280-010-1396-8, 20658136.
53. Zhao Q, Wang J, Zou MJ, Hu R, Zhao L, Qiang L, Rong JJ, You QD, Guo QL. Wogonin potentiates the antitumor effects of low dose 5-fluorouracil against gastric cancer through induction of apoptosis by down-regulation of NF-kappaB and regulation of its metabolism. Toxicol Lett 2010, 197:201-210. 10.1016/j.toxlet.2010.05.019, 20570612.
54. Li-Weber M. New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treatment Reviews 2009, 35:57-68. 10.1016/j.ctrv.2008.09.005, 19004559.
55. Rajamanickam S, Velmurugan B, Kaur M, Singh RP, Agarwal R. Chemoprevention of intestinal tumorigenesis in APCmin/+ mice by silibinin. Cancer Res 2010, 70:2368-2378. 10.1158/0008-5472.CAN-09-3249, 2840193, 20215518.
56. Singh RP, Raina K, Deep G, Chan D, Agarwal R. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 2009, 15:613-621. 10.1158/1078-0432.CCR-08-1846, 2629529, 19147767.
57. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008, 14:7773-7780. 10.1158/1078-0432.CCR-08-1309, 2639624, 19047104.
58. Tiwari P, Kumar A, Balakrishnan S, Kushwaha HS, Mishra KP. Silibinin-induced apoptosis in MCF7 and T47D human breast carcinoma cells involves caspase-8 activation and mitochondrial pathway. Cancer Invest 2011, 29:12-20. 10.3109/07357907.2010.535053, 21166494.
59. Cui W, Gu F, Hu KQ. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009, 15:1943-1950. 10.3748/wjg.15.1943, 2675083, 19399925.
60. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008, 68:6822-6830. 10.1158/0008-5472.CAN-08-1332, 2587411, 18701508.
61. Mateen S, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol Carcinog 2010, 49:247-258. 3049548, 19908243.
62. Li L, Zeng J, Gao Y, He D. Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs 2010, 19:243-255. 10.1517/13543780903533631, 20047507.
63. Agarwal C, Tyagi A, Kaur M, Agarwal R. Silibinin inhibits constitutive activation of Stat3, and causes caspase activation and apoptotic death of human prostate carcinoma DU145 cells. Carcinogenesis 2007, 28:1463-1470. 10.1093/carcin/bgm042, 17341659.
64. Wang X, Gocek E, Novik V, Harrison JS, Danilenko M, Studzinski GP. Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3). Cell Cycle 2010, 9:4542-4551.
65. Ong ES, Woo SO, Yong YL. Pressurized liquid extraction of berberine and aristolochic acids in medicinal plants. J Chromatogr A 2000, 904:57-64. 10.1016/S0021-9673(00)00914-6, 11209901.
66. Lee IA, Hyun YJ, Kim DH. Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobacterial growth and NF-kappaB activation. Eur J Pharmacol 2010, 648:162-170. 10.1016/j.ejphar.2010.08.046, 20828550.
67. Liu X, Li G, Zhu H, Huang L, Liu Y, Ma C, Qin C. Beneficial effect of berberine on hepatic insulin resistance in diabetic hamsters possibly involves in SREBPs, LXRalpha and PPARalpha transcriptional programs. Endocr J 2010, 57:881-893. 10.1507/endocrj.K10E-043, 20724798.
68. Zhou J, Zhou S. Berberine regulates peroxisome proliferator-activated receptors and positive transcription elongation factor b expression in diabetic adipocytes. Eur J Pharmacol 2010, 649:390-397. 10.1016/j.ejphar.2010.09.030, 20868663.
69. Wu M, Wang J, Liu LT. Advance of studies on anti-atherosclerosis mechanism of berberine. Chin J Integr Med 2010, 16:188-192. 10.1007/s11655-010-0188-7, 20473748.
70. Zhao L, Li W, Han F, Hou L, Baillargeon JP, Kuang H, Wang Y, Wu X. Berberine reduces insulin resistance induced by dexamethasone in theca cells in vitro. Fertil Steril 2011, 95:461-463. 10.1016/j.fertnstert.2010.07.1090, 20840879.
71. Remppis A, Bea F, Greten HJ, Buttler A, Wang H, Zhou Q, Preusch MR, Enk R, Ehehalt R, Katus H, Blessing E. Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. Mediators Inflamm 2010, 2010:194896. 2905940, 20652055.
72. Choi MS, Yuk DY, Oh JH, Jung HY, Han SB, Moon DC, Hong JT. Berberine inhibits human neuroblastoma cell growth through induction of p53-dependent apoptosis. Anticancer Res 2008, 28:3777-3784.
73. Ho YT, Lu CC, Yang JS, Chiang JH, Li TC, Ip SW, Hsia TC, Liao CL, Lin JG, Wood WG, Chung JG. Berberine induced apoptosis via promoting the expression of caspase-8, -9 and -3, apoptosis-inducing factor and endonuclease G in SCC-4 human tongue squamous carcinoma cancer cells. Anticancer Res 2009, 29:4063-4070.
74. Hsu WH, Hsieh YS, Kuo HC, Teng CY, Huang HI, Wang CJ, Yang SF, Liou YS, Kuo WH. Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL. Arch Toxicol 2007, 81:719-728. 10.1007/s00204-006-0169-y, 17673978.
75. James MA, Fu H, Liu Y, Chen DR, You M. Dietary administration of berberine or Phellodendron amurense extract inhibits cell cycle progression and lung tumorigenesis. Mol Carcinog 2011, 50:1-7. 10.1002/mc.20690, 21061266.
76. Patil JB, Kim J, Jayaprakasha GK. Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur J Pharmacol 2010, 645:70-78. 10.1016/j.ejphar.2010.07.037, 20691179.
77. Auyeung KK, Ko JK. Coptis chinensis inhibits hepatocellular carcinoma cell growth through nonsteroidal anti-inflammatory drug-activated gene activation. Int J Mol Med 2009, 24:571-577.
78. Yu FS, Yang JS, Lin HJ, Yu CS, Tan TW, Lin YT, Lin CC, Lu HF, Chung JG. Berberine inhibits WEHI-3 leukemia cells in vivo. In Vivo 2007, 21:407-412.
79. Meeran SM, Katiyar S, Katiyar SK. Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol 2008, 229:33-43. 10.1016/j.taap.2007.12.027, 18275980.
80. Pandey MK, Sung B, Kunnumakkara AB, Sethi G, Chaturvedi MM, Aggarwal BB. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res 2008, 68:5370-5379. 10.1158/0008-5472.CAN-08-0511, 18593939.
81. Qin Y, Pang JY, Chen WH, Zhao ZZ, Liu L, Jiang ZH. Inhibition of DNA topoisomerase I by natural and synthetic mono- and dimeric protoberberine alkaloids. Chem Biodivers 2007, 4:481-487. 10.1002/cbdv.200790040, 17372950.
82. Katiyar SK, Meeran SM, Katiyar N, Akhtar S. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo. Mol Carcinog 2009, 48:24-37. 10.1002/mc.20453, 18459128.
83. Maiti M, Kumar GS. Polymorphic nucleic Acid binding of bioactive isoquinoline alkaloids and their role in cancer. J Nucleic Acids 2010, 2010. 2915887, 20814427.
84. Bhadra K, Kumar GS. Therapeutic potential of nucleic acid-binding isoquinoline alkaloids: Binding aspects and implications for drug design. Med Res Rev 2010,
85. Tian X, Song Y, Dong H, Ye B. Interaction of anticancer herbal drug berberine with DNA immobilized on the glassy carbon electrode. Bioelectrochemistry 2008, 73:18-22. 10.1016/j.bioelechem.2008.02.005, 18455966.
86. Serafim TL, Oliveira PJ, Sardao VA, Perkins E, Parke D, Holy J. Different concentrations of berberine result in distinct cellular localization patterns and cell cycle effects in a melanoma cell line. Cancer Chemother Pharmacol 2008, 61:1007-1018. 10.1007/s00280-007-0558-9, 17661039.
87. Kim JB, Yu JH, Ko E, Lee KW, Song AK, Park SY, Shin I, Han W, Noh DY. The alkaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 and MDA-MB-231 breast cancer cell lines by inducing cell cycle arrest. Phytomedicine 2010, 17:436-440. 10.1016/j.phymed.2009.08.012, 19800775.
88. Eom KS, Hong JM, Youn MJ, So HS, Park R, Kim JM, Kim TY. Berberine induces G1 arrest and apoptosis in human glioblastoma T98G cells through mitochondrial/caspases pathway. Biol Pharm Bull 2008, 31:558-562. 10.1248/bpb.31.558, 18379040.
89. Pereira CV, Machado NG, Oliveira PJ. Mechanisms of berberine (natural yellow 18)-induced mitochondrial dysfunction: interaction with the adenine nucleotide translocator. Toxicol Sci 2008, 105:408-417. 10.1093/toxsci/kfn131, 18599498.
90. Wang N, Feng Y, Zhu M, Tsang CM, Man K, Tong Y, Tsao SW. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: the cellular mechanism. J Cell Biochem 2010, 111:1426-1436. 10.1002/jcb.22869, 20830746.
91. Peng PL, Kuo WH, Tseng HC, Chou FP. Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int J Radiat Oncol Biol Phys 2008, 70:529-542. 10.1016/j.ijrobp.2007.08.034, 18207031.
92. Singh T, Vaid M, Katiyar N, Sharma S, Katiyar SK. Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E and prostaglandin E receptors. Carcinogenesis 2011, 32:86-92. 10.1093/carcin/bgq215, 20974686.
93. Tsang CM, Lau EP, Di K, Cheung PY, Hau PM, Ching YP, Wong YC, Cheung AL, Wan TS, Tong Y, Tsao SW, Feng Y. Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells. Int J Mol Med 2009, 24:131-138.
94. Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, Wang W, Xie C, Meng J, Wang L, Wu B, Liu S, Tian D, Zhu F, He Z, Deng F, Cao Y. Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. J Biol Chem 2009, 284:27456-27466. 10.1074/jbc.M109.033795, 2785675, 19651779.
95. Lin TH, Kuo HC, Chou FP, Lu FJ. Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer 2008, 8:58. 10.1186/1471-2407-8-58, 2275285, 18294404.
96. Kim DW, Ahan SH, Kim TY. Enhancement of Arsenic Trioxide (As(2)O(3))- Mediated Apoptosis Using Berberine in Human Neuroblastoma SH-SY5Y Cells. J Korean Neurosurg Soc 2007, 42:392-399. 10.3340/jkns.2007.42.5.392, 2588187, 19096576.
97. Youn MJ, So HS, Cho HJ, Kim HJ, Kim Y, Lee JH, Sohn JS, Kim YK, Chung SY, Park R. Berberine, a natural product, combined with cisplatin enhanced apoptosis through a mitochondria/caspase-mediated pathway in HeLa cells. Biol Pharm Bull 2008, 31:789-795. 10.1248/bpb.31.789, 18451495.
98. Hur JM, Hyun MS, Lim SY, Lee WY, Kim D. The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells. J Cell Biochem 2009, 107:955-964. 10.1002/jcb.22198, 19492307.
99. Zhang X, Gu L, Li J, Shah N, He J, Yang L, Hu Q, Zhou M. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res 2010, 70:9895-9904. 10.1158/0008-5472.CAN-10-1546, 20935220.
100. Gui SY, Wu L, Peng DY, Liu QY, Yin BP, Shen JZ. Preparation and evaluation of a microemulsion for oral delivery of berberine. Pharmazie 2008, 63:516-519.
101. Cheng Z, Chen AF, Wu F, Sheng L, Zhang HK, Gu M, Li YY, Zhang LN, Hu LH, Li JY, Li J. 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Bioorg Med Chem 2010, 18:5915-5924. 10.1016/j.bmc.2010.06.085, 20663675.
102. Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol 2002, 91:193-197. 10.1034/j.1600-0773.2002.t01-1-910403.x, 12530470.
103. Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008, 14:5519-5530. 10.1158/1078-0432.CCR-08-0197, 18765544.
104. Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther 2008, 7:1017-1023. 10.4161/cbt.7.7.6035, 18414062.
105. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD, Funk JO. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003, 64:382-394. 10.1124/mol.64.2.382, 12869643.
106. Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J. Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells. Biochem Pharmacol 2010, 80:22-30. 10.1016/j.bcp.2010.02.016, 20206143.
107. Chen H, Sun B, Pan S, Jiang H, Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 2009, 20:131-140. 10.1097/CAD.0b013e3283212ade, 19209030.
108. Li LN, Zhang HD, Yuan SJ, Tian ZY, Wang L, Sun ZX. Artesunate attenuates the growth of human colorectal carcinoma and inhibits hyperactive Wnt/beta-catenin pathway. Int J Cancer 2007, 121:1360-1365. 10.1002/ijc.22804, 17520675.
109. Du JH, Zhang HD, Ma ZJ, Ji KM. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 2010, 65:895-902. 10.1007/s00280-009-1095-5, 2824122, 19690861.
110. Mercer AE, Copple IM, Maggs JL, O'Neill PM, Park BK. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem 2011, 286:987-996. 10.1074/jbc.M110.144188, 21059641.
111. Zhang S, Chen H, Gerhard GS. Heme synthesis increases artemisinin -induced radical formation and cytotoxicity that can be suppressed by superoxide scavengers. Chem Biol Interact 2010, 186:30-35. 10.1016/j.cbi.2010.03.021, 20361947.
112. Zhang S, Gerhard GS. Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. PLoS ONE 2009, 4:e7472. 10.1371/journal.pone.0007472, 2764339, 19862332.
113. Efferth T, Benakis A, Romero MR, Tomicic M, Rauh R, Steinbach D, Hafer R, Stamminger T, Oesch F, Kaina B, Marschall M. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med 2004, 37:998-1009. 10.1016/j.freeradbiomed.2004.06.023, 15336316.
114. Kelter G, Steinbach D, Konkimalla VB, Tahara T, Taketani S, Fiebig HH, Efferth T. Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS ONE 2007, 2:e798. 10.1371/journal.pone.0000798, 1949049, 17726528.
115. Lu JJ, Chen SM, Zhang XW, Ding J, Meng LH. The anti-cancer activity of dihydroartemisinin is associated with induction of iron-dependent endoplasmic reticulum stress in colorectal carcinoma HCT116 cells. Invest New Drugs 2010,
116. Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul W, Slade D, Galal AM, Newton DL, Bumke MA. Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer 2009, 125:1266-1275. 10.1002/ijc.24496, 2752979, 19533749.
117. Jiao Y, Ge CM, Meng QH, Cao JP, Tong J, Fan SJ. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta pharmacol Sin 2007, 28:1045-1056. 10.1111/j.1745-7254.2007.00612.x, 17588342.
118. Handrick R, Ontikatze T, Bauer KD, Freier F, Rubel A, Durig J, Belka C, Jendrossek V. Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther 2010, 9:2497-2510. 10.1158/1535-7163.MCT-10-0051, 20663933.
119. Chen T, Li M, Zhang R, Wang H. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 2009, 13:1358-1370. 10.1111/j.1582-4934.2008.00360.x, 18466355.
120. He Q, Shi J, Shen XL, An J, Sun H, Wang L, Hu YJ, Sun Q, Fu LC, Sheikh MS, Huang Y. Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biol Ther 2010, 9:819-824. 10.4161/cbt.9.10.11552, 20224297.
121. Zhou HJ, Wang WQ, Wu GD, Lee J, Li A. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol 2007, 47:131-138. 10.1016/j.vph.2007.05.002, 17581794.
122. Chen HH, Zhou HJ, Wang WQ, Wu GD. Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemother Pharmacol 2004, 53:423-432. 10.1007/s00280-003-0751-4, 15132130.
123. Anfosso L, Efferth T, Albini A, Pfeffer U. Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. Pharmacogenomics J 2006, 6:269-278.
124. Lee J, Zhou HJ, Wu XH. Dihydroartemisinin downregulates vascular endothelial growth factor expression and induces apoptosis in chronic myeloid leukemia K562 cells. Cancer Chemother Pharmacol 2006, 57:213-220. 10.1007/s00280-005-0002-y, 16075280.
125. Buommino E, Baroni A, Canozo N, Petrazzuolo M, Nicoletti R, Vozza A, Tufano MA. Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production. Invest New Drugs 2009, 27:412-418. 10.1007/s10637-008-9188-2, 18956140.
126. Rasheed SA, Efferth T, Asangani IA, Allgayer H. First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 2010, 127:1475-1485. 10.1002/ijc.25315, 20232396.
127. Efferth T, Ramirez T, Gebhart E, Halatsch ME. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem Pharmacol 2004, 67:1689-1700. 10.1016/j.bcp.2003.12.035, 15081868.
128. Li QQ, Wang GD, Huang FR, Banda M, Reed E. Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells. J Pharm Pharmacol 2010, 62:1018-1027.
129. Wang G, Li X, Huang F, Zhao J, Ding H, Cunningham C, Coad JE, Flynn DC, Reed E, Li QQ. Antitumor effect of beta-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci 2005, 62:881-893. 10.1007/s00018-005-5017-3, 15868411.
130. Li X, Wang G, Zhao J, Ding H, Cunningham C, Chen F, Flynn DC, Reed E, Li QQ. Antiproliferative effect of beta-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci 2005, 62:894-904. 10.1007/s00018-005-5027-1, 15868412.
131. Zhao J, Li QQ, Zou B, Wang G, Li X, Kim JE, Cuff CF, Huang L, Reed E, Gardner K. In vitro combination characterization of the new anticancer plant drug beta-elemene with taxanes against human lung carcinoma. Inter J Oncol 2007, 31:241-252.
132. Yao YQ, Ding X, Jia YC, Huang CX, Wang YZ, Xu YH. Anti-tumor effect of beta-elemene in glioblastoma cells depends on p38 MAPK activation. Cancer Lett 2008, 264:127-134. 10.1016/j.canlet.2008.01.049, 18442668.
133. Tao L, Zhou L, Zheng L, Yao M. Elemene displays anti-cancer ability on laryngeal cancer cells in vitro and in vivo. Cancer Chemother Pharmacol 2006, 58:24-34. 10.1007/s00280-005-0137-x, 16283311.
134. Wu XS, Xie T, Lin J, Fan HZ, Huang-Fu HJ, Ni LF, Yan HF. An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas. J Pharm Pharmacol 2009, 61:1653-1656.
135. Liao WL, Du Z, Zhang T, Guo XL, Wen YT, Yu Q, Luo AQ, Li WM. Qualitative and quantitative evaluation of Rabdosia Rubescens (Hemls.) Hara of different areas. Central South Pharmacy 2010, 12:912-915.
136. Liu JJ, Huang RW, Lin DJ, Wu XY, Peng J, Pan XL, Lin Q, Hou M, Zhang MH, Chen F. Antiproliferation effects of oridonin on HPB-ALL cells and its mechanisms of action. Am J Hematol 2006, 81:86-94. 10.1002/ajh.20524, 16432862.
137. Liu JJ, Huang RW, Lin DJ, Peng J, Wu XY, Pan XL, Li MQ, Lin Q. Anti-proliferative effects of oridonin on SPC-A-1 cells and its mechanism of action. J Int Med Res 2004, 32:617-625.
138. Cui Q, Tashiro S, Onodera S, Ikejima T. Augmentation of oridonin-induced apoptosis observed with reduced autophagy. J Pharmacol Sci 2006, 101:230-239. 10.1254/jphs.FPJ06003X, 16861822.
139. Wu JN, Huang J, Yang J, Tashiro S, Onodera S, Ikejima T. Caspase inhibition augmented oridonin-induced cell death in murine fibrosarcoma l929 by enhancing reactive oxygen species generation. J Pharmacol Sci 2008, 108:32-39. 10.1254/jphs.FP0072079, 18818479.
140. Kang N, Zhang JH, Qiu F, Tashiro S, Onodera S, Ikejima T. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett 2010, 294:147-158. 10.1016/j.canlet.2010.01.032, 20202741.
141. Zhang Y, Wu Y, Tashiro S, Onodera S, Ikejima T. Involvement of PKC signal pathways in oridonin-induced autophagy in HeLa cells: a protective mechanism against apoptosis. Biochem Biophys Res Commun 2009, 378:273-278. 10.1016/j.bbrc.2008.11.038, 19026988.
142. Wang H, Ye Y, Pan SY, Zhu GY, Li YW, Fong DW, Yu ZL. Proteomic identification of proteins involved in the anticancer activities of oridonin in HepG2 cells. Phytomedicine 2011, 18:163-169. 10.1016/j.phymed.2010.06.011, 20724128.
143. Kang N, Zhang JH, Qiu F, Chen S, Tashiro S, Onodera S, Ikejima T. Induction of G(2)/M phase arrest and apoptosis by oridonin in human laryngeal carcinoma cells. J Nat Prod 2010, 73:1058-1063. 10.1021/np9008199, 20496901.
144. Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S, Ikejima T. Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells. Biol Pharm Bull 2006, 29:1873-1879. 10.1248/bpb.29.1873, 16946501.
145. Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induces human epidermoid carcinoma A431 cell apoptosis through tyrosine kinase and mitochondrial pathway. J Asian Nat Prod Res 2008, 10:77-87. 10.1080/10286020701273866, 18058384.
146. Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induced A375-S2 cell apoptosis via bax-regulated caspase pathway activation, dependent on the cytochrome c/caspase-9 apoptosome. J Asian Nat Prod Res 2004, 6:127-138. 10.1080/1028602031000147375, 15008459.
147. Zhang CL, Wu LJ, Zuo HJ, Tashiro S, Onodera S, Ikejima T. Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation. J Pharmacol Sci 2004, 96:155-163. 10.1254/jphs.FPJ04008X, 15492467.
148. Liu J, Huang R, Lin D, Wu X, Peng J, Lin Q, Pan X, Zhang M, Hou M, Chen F. Apoptotic effect of oridonin on NB4 cells and its mechanism. Leuk Lymphoma 2005, 46:593-597. 10.1080/10428190400019800, 16019488.
149. Zhang CL, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin induces a caspase-independent but mitochondria- and MAPK-dependent cell death in the murine fibrosarcoma cell line L929. Biol Pharm Bull 2004, 27:1527-1531. 10.1248/bpb.27.1527, 15467189.
150. Cui Q, Yu JH, Wu JN, Tashiro S, Onodera S, Minami M, Ikejima T. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells. Acta Pharmacol Sin 2007, 28:1057-1066. 10.1111/j.1745-7254.2007.00588.x, 17588343.
151. Cheng Y, Qiu F, Ikejima T. Molecular mechanisms of oridonin-induced apoptosis and autophagy in murine fibrosarcoma L929 cells. Autophagy 2009, 5:430-431. 10.4161/auto.5.3.7896, 19202353.
152. Cheng Y, Qiu F, Ye YC, Tashiro S, Onodera S, Ikejima T. Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-Ras-Raf-JNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys 2009, 490:70-75. 10.1016/j.abb.2009.08.011, 19699177.
153. Wang HJ, Li D, Yang FY, Tashiro S, Onodera S, Ikejima T. Oridonin induces human melanoma A375-S2 cell death partially through inhibiting insulin-like growth factor 1 receptor signaling. J Asian Nat Prod Res 2008, 10:787-798.
154. Li D, Wu LJ, Tashiro S, Onodera S, Ikejima T. Oridonin inhibited the tyrosine kinase activity and induced apoptosis in human epidermoid carcinoma A431 cells. Biol Pharm Bull 2007, 30:254-260. 10.1248/bpb.30.254, 17268061.
155. Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP, Taguchi H. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol Cancer Ther 2005, 4:578-586. 10.1158/1535-7163.MCT-04-0277, 15827331.
156. Gao FH, Hu XH, Li W, Liu H, Zhang YJ, Guo ZY, Xu MH, Wang ST, Jiang B, Liu F, Zhao YZ, Fang Y, Chen FY, Wu YL. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer 2010, 10:610. 10.1186/1471-2407-10-610, 2992521, 21054888.
157. Cui Q, Tashiro S, Onodera S, Minami M, Ikejima T. Autophagy preceded apoptosis in oridonin-treated human breast cancer MCF-7 cells. Biol Pharm Bull 2007, 30:859-864. 10.1248/bpb.30.859, 17473426.
158. Li D, Cui Q, Chen SG, Wu LJ, Tashiro S, Onodera S, Ikejima T. Inactivation of ras and changes of mitochondrial membrane potential contribute to oridonin-induced autophagy in a431 cells. J Pharmacol Sci 2007, 105:22-33. 10.1254/jphs.FPJ06022X, 17895587.
159. Zhang Y, Wu Y, Wu D, Tashiro S, Onodera S, Ikejima T. NF-kappab facilitates oridonin-induced apoptosis and autophagy in HT1080 cells through a p53-mediated pathway. Arch Biochem Biophys 2009, 489:25-33. 10.1016/j.abb.2009.07.017, 19646415.
160. Cheng Y, Qiu F, Ye YC, Guo ZM, Tashiro S, Onodera S, Ikejima T. Autophagy inhibits reactive oxygen species-mediated apoptosis via activating p38-nuclear factor-kappa B survival pathways in oridonin-treated murine fibrosarcoma L929 cells. FEBS J 2009, 276:1291-1306. 10.1111/j.1742-4658.2008.06864.x, 19187231.
161. Wang MY, Lin C, Zhang TM. Effects of oridonin on DNA, RNA and protein syntheses of leukemia L 1210 cells studied by autoradiography. Zhongguo Yao Li Xue Bao 1987, 8:164-165.
162. Liu JJ, Wu XY, Peng J, Pan XL, Lu HL. Antiproliferation effects of oridonin on HL-60 cells. Ann Hematol 2004, 83:691-695. 10.1007/s00277-004-0919-y, 15322762.
163. Lou H, Zhang X, Gao L, Feng F, Wang J, Wei X, Yu Z, Zhang D, Zhang Q. In vitro and in vivo antitumor activity of oridonin nanosuspension. Int J Pharm 2009, 379:181-186. 10.1016/j.ijpharm.2009.06.022, 19563872.
164. Zhou GB, Kang H, Wang L, Gao L, Liu P, Xie J, Zhang FX, Weng XQ, Shen ZX, Chen J, Gu LJ, Yan M, Zhang DE, Chen SJ, Wang ZY, Chen Z. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 2007, 109:3441-3450. 10.1182/blood-2006-06-032250, 1852250, 17197433.
165. He MF, Liu L, Ge W, Shaw PC, Jiang R, Wu LW, But PP. Antiangiogenic activity of Tripterygium wilfordii and its terpenoids. J Ethnopharmacol 2009, 121:61-68. 10.1016/j.jep.2008.09.033, 18996177.
166. Li H, Takai N, Yuge A, Furukawa Y, Tsuno A, Tsukamoto Y, Kong S, Moriyama M, Narahara H. Novel target genes responsive to the anti-growth activity of triptolide in endometrial and ovarian cancer cells. Cancer Lett 2010, 297:198-206. 10.1016/j.canlet.2010.05.012, 20547442.
167. Zhao F, Chen Y, Zeng L, Li R, Zeng R, Wen L, Liu Y, Zhang C. Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. Eur J Pharmacol 2010, 646:1-11. 10.1016/j.ejphar.2010.05.034, 20547150.
168. Zhou GS, Hu Z, Fang HT, Zhang FX, Pan XF, Chen XQ, Hu AM, Xu L, Zhou GB. Biologic activity of triptolide in t(8;21) acute myeloid leukemia cells. Leuk Res 2011, 35:214-218. 10.1016/j.leukres.2010.07.013, 20691473.
169. Zhu W, Hu H, Qiu P, Yan G. Triptolide induces apoptosis in human anaplastic thyroid carcinoma cells by a p53-independent but NF-kappaB- related mechanism. Oncol Rep 2009, 22:1397-1401.
170. Zhou GX, Ding XL, Huang JF, Zhang H, Wu SB. Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines. Biochim Biophys Acta 2007, 1770:1021-1027.
171. Clawson KA, Borja-Cacho D, Antonoff MB, Saluja AK, Vickers SM. Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma. J Surg Res 2010, 163:244-249. 10.1016/j.jss.2010.03.067, 20691980.
172. Carter BZ, Mak DH, Schober WD, McQueen T, Harris D, Estrov Z, Evans RL, Andreeff M. Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells. Blood 2006, 108:630-637. 10.1182/blood-2005-09-3898, 1895484, 16556893.
173. Wan CK, Wang C, Cheung HY, Yang M, Fong WF. Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells. Cancer Lett 2006, 241:31-41. 10.1016/j.canlet.2005.10.001, 16316721.
174. Johnson SM, Wang X, Mark Evers B. Triptolide Inhibits Proliferation and Migration of Colon Cancer Cells by Inhibition of Cell Cycle Regulators and Cytokine Receptors. J Surg Res 2011, 168:197-205. 10.1016/j.jss.2009.07.002, 19922946.
175. Chang HJ, Kim MH, Baek MK, Park JS, Chung IJ, Shin BA, Ahn BW, Jung YD. Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-kappaB signaling in human gastric AGS cells. Anticancer Res 2007, 27:3411-3417.
176. Zhu W, He S, Li Y, Qiu P, Shu M, Ou Y, Zhou Y, Leng T, Xie J, Zheng X, Xu D, Su X, Yan G. Anti-angiogenic activity of triptolide in anaplastic thyroid carcinoma is mediated by targeting vascular endothelial and tumor cells. Vascul Pharmacol 2010, 52:46-54. 10.1016/j.vph.2009.10.006, 19854299.
177. Liang M, Fu J. Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. Cancer Lett 2008, 270:337-341. 10.1016/j.canlet.2008.05.025, 18572307.
178. Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, Yang J, Underhill CB, Zhang L. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003, 2:65-72.
179. Zhang C, Cui GH, Liu F, Wu QL, Chen Y. Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro. Acta pharmacologica Sinica 2006, 27:1438-1446. 10.1111/j.1745-7254.2006.00415.x, 17049119.
180. Tang XY, Zhu YQ, Tao WH, Wei B, Lin XL. Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J 2007, 83:338-343. 10.1136/pgmj.2006.055426, 2600066, 17488865.
181. Yang SW, Wang W, Xie XY, Zhu WP, Li FQ. In vitro synergistic cytotoxic effect of triptolide combined with hydroxycamptothecin on pancreatic cancer cells. Am J Chin Med 2011, 39:121-134. 10.1142/S0192415X11008695, 21213403.
182. Pigneux A, Mahon FX, Uhalde M, Jeanneteau M, Lacombe F, Milpied N, Reiffers J, Belloc F. Triptolide cooperates with chemotherapy to induce apoptosis in acute myeloid leukemia cells. Exp Hematol 2008, 36:1648-1659. 10.1016/j.exphem.2008.08.002, 18922616.
183. Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC, Andreeff M. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood 2008, 111:3742-3750. 10.1182/blood-2007-05-091504, 2275030, 18187663.
184. Wang W, Yang S, Su Y, Xiao Z, Wang C, Li X, Lin L, Fenton BM, Paoni SF, Ding I, Keng P, Okunieff P, Zhang L. Enhanced antitumor effect of combined triptolide and ionizing radiation. Clin Cancer Res 2007, 13:4891-4899. 10.1158/1078-0432.CCR-07-0416, 17699869.
185. Wang X, Li L, Wang B, Xiang J. Effects of ursolic acid on the proliferation and apoptosis of human ovarian cancer cells. J Huazhong Uni Sci Technol Med Sci 2009, 29:761-764.
186. Yang L, Liu X, Lu Z, Yuet-Wa Chan J, Zhou L, Fung KP, Wu P, Wu S. Ursolic acid induces doxorubicin-resistant HepG2 cell death via the release of apoptosis-inducing factor. Cancer Lett 2010, 298:128-138. 10.1016/j.canlet.2010.06.010, 20630652.
187. De Angel RE, Smith SM, Glickman RD, Perkins SN, Hursting SD. Antitumor effects of ursolic acid in a mouse model of postmenopausal breast cancer. Nutr Cancer 2010, 62:1074-1086. 10.1080/01635581.2010.492092, 21058195.
188. Meng Y, Song Y, Yan Z, Xia Y. Synthesis and in vitro cytotoxicity of novel ursolic acid derivatives. Molecules (Basel, Switzerland) 2010, 15:4033-4040.
189. Kwon SH, Park HY, Kim JY, Jeong IY, Lee MK, Seo KI. Apoptotic action of ursolic acid isolated from Corni fructus in RC-58T/h/SA#4 primary human prostate cancer cells. Bioorg Med Chem Lett 2010, 20:6435-6438. 10.1016/j.bmcl.2010.09.073, 20943386.
190. Zhang Y, Kong C, Zeng Y, Wang L, Li Z, Wang H, Xu C, Sun Y. Ursolic acid induces PC-3 cell apoptosis via activation of JNK and inhibition of Akt pathways in vitro. Mol Carcinog 2010, 49:374-385.
191. Yeh CT, Wu CH, Yen GC. Ursolic acid, a naturally occurring triterpenoid, suppresses migration and invasion of human breast cancer cells by modulating c-Jun N-terminal kinase, Akt and mammalian target of rapamycin signaling. Mol Nutr Food Res 2010, 54:1285-1295. 10.1002/mnfr.200900414, 20352621.
192. Huang HC, Huang CY, Lin-Shiau SY, Lin JK. Ursolic acid inhibits IL-1beta or TNF-alpha-induced C6 glioma invasion through suppressing the association ZIP/p62 with PKC-zeta and downregulating the MMP-9 expression. Mol Carcinog 2009, 48:517-531. 10.1002/mc.20490, 18973186.
193. Kanjoormana M, Kuttan G. Antiangiogenic activity of ursolic acid. Integr Cancer Ther 2010, 9:224-235. 10.1177/1534735410367647, 20462855.
194. Lin CC, Huang CY, Mong MC, Chan CY, Yin MC. Antiangiogenic Potential of Three Triterpenic Acids in Human Liver Cancer Cells. J Agric Food Chem 2010, 755-762.
195. Wu Z, Wu L, Li L, Tashiro S, Onodera S, Ikejima T. p53-mediated cell cycle arrest and apoptosis induced by shikonin via a caspase-9-dependent mechanism in human malignant melanoma A375-S2 cells. J Pharmacol Sci 2004, 94:166-176. 10.1254/jphs.94.166, 14978355.
196. Wu Z, Wu LJ, Li LH, Tashiro S, Onodera S, Ikejima T. Shikonin regulates HeLa cell death via caspase-3 activation and blockage of DNA synthesis. J Asian Nat Prod Res 2004, 6:155-166. 10.1080/1028602032000169622, 15224412.
197. Yeh CC, Kuo HM, Li TM, Lin JP, Yu FS, Lu HF, Chung JG, Yang JS. Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24). In Vivo 2007, 21:1011-1019.
198. Yoon Y, Kim YO, Lim NY, Jeon WK, Sung HJ. Shikonin, an ingredient of Lithospermum erythrorhizon induced apoptosis in HL60 human premyelocytic leukemia cell line. Planta Med 1999, 65:532-535. 10.1055/s-1999-14010, 10483373.
199. Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, Luo J, Hu X. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007, 6:1641-1649. 10.1158/1535-7163.MCT-06-0511, 17513612.
200. Han W, Xie J, Li L, Liu Z, Hu X. Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis 2009, 14:674-686. 10.1007/s10495-009-0334-x, 19288276.
201. Min R, Tong J, Wenjun Y, Wenhu D, Xiaojian Z, Jiacai H, Jian Z, Wantao C, Chenping Z. Growth inhibition and induction of apoptosis in human oral squamous cell carcinoma Tca-8113 cell lines by Shikonin was partly through the inactivation of NF-kappaB pathway. Phytother Res 2008, 22:407-415. 10.1002/ptr.2340, 18167055.
202. Nie YK, Zhu LS, Yu HM. Shikonin inhibits the proliferation and induces the apoptosis of human HepG2 cells. Can J Physiol Pharm 2010, 88:1138-1146.
203. Chang IC, Huang YJ, Chiang TI, Yeh CW, Hsu LS. Shikonin Induces Apoptosis through Reactive Oxygen Species/Extracellular Signal- Regulated Kinase Pathway in Osteosarcoma Cells. Biol Pharm Bull 2010, 33:816-824. 10.1248/bpb.33.816, 20460760.
204. Mao X, Yu CR, Li WH, Li WX. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res 2008, 18:879-888. 10.1038/cr.2008.86, 18663379.
205. Yang H, Zhou P, Huang H, Chen D, Ma N, Cui QC, Shen S, Dong W, Zhang X, Lian W, Wang X, Dou QP, Liu J. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 2009, 124:2450-2459. 10.1002/ijc.24195, 2707765, 19165859.
206. Yang F, Chen Y, Duan W, Zhang C, Zhu H, Ding J. SH-7, a new synthesized shikonin derivative, exerting its potent antitumor activities as a topoisomerase inhibitor. Int J Cancer 2006, 119:1184-1193. 10.1002/ijc.21943, 16570288.
207. Yao Y, Zhou Q. A novel antiestrogen agent Shikonin inhibits estrogen- dependent gene transcription in human breast cancer cells. Breast Cancer Res Tr 2010, 121:233-240.
208. Yao YA, Brodie AMH, Davidson NE, Kensler TW, Zhou Q. Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Tr 2010, 124:585-591.
209. Min R, Zun Z, Min Y, Wenhu D, Wenjun Y, Chenping Z. Shikonin inhibits tumor invasion via down-regulation of NF-kappaB-mediated MMP-9 expression in human ACC-M cells. Oral Dis 2011, 17:362-369. 10.1111/j.1601-0825.2010.01758.x, 21029262.
210. Wang L, Li D, Bao C, You J, Wang Z, Shi Y, Zhang H. Ultrasonic extraction and separation of anthraquinones from Rheum palmatum L. Ultrason Sonochem 2008, 15:738-746. 10.1016/j.ultsonch.2007.12.008, 18280764.
211. Srinivas G, Babykutty S, Sathiadevan PP, Srinivas P. Molecular mechanism of emodin action: transition from laxative ingredient to an antitumor agent. Med Res Rev 2007, 27:591-608. 10.1002/med.20095, 17019678.
212. Chun-Guang W, Jun-Qing Y, Bei-Zhong L, Dan-Ting J, Chong W, Liang Z, Dan Z, Yan W. Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur J Pharmacol 2010, 627:33-41. 10.1016/j.ejphar.2009.10.035, 19857484.
213. Muto A, Hori M, Sasaki Y, Saitoh A, Yasuda I, Maekawa T, Uchida T, Asakura K, Nakazato T, Kaneda T, Kizaki M, Ikeda Y, Yoshida T. Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol Cancer Ther 2007, 6:987-994.
214. Su YT, Chang HL, Shyue SK, Hsu SL. Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. Biochem Pharmacol 2005, 70:229-241. 10.1016/j.bcp.2005.04.026, 15941563.
215. Cha TL, Qiu L, Chen CT, Wen Y, Hung MC. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res 2005, 65:2287-2295. 10.1158/0008-5472.CAN-04-3250, 15781642.
216. Li Y, Luan Y, Qi X, Li M, Gong L, Xue X, Wu X, Wu Y, Chen M, Xing G, Yao J, Ren J. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II. Toxicol Sci 2010, 118:435-443. 10.1093/toxsci/kfq282, 20855424.
217. Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Lin YW. Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol 2010, 79:655-664. 10.1016/j.bcp.2009.09.024, 19799875.
218. Kwak HJ, Park MJ, Park CM, Moon SI, Yoo DH, Lee HC, Lee SH, Kim MS, Lee HW, Shin WS, Park IC, Rhee CH, Hong SI. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int J Cancer 2006, 118:2711-2720. 10.1002/ijc.21641, 16388516.
219. Huang Q, Shen HM, Ong CN. Emodin inhibits tumor cell migration through suppression of the phosphatidylinositol 3-kinase-Cdc42/Rac1 pathway. Cell Mol Life Sci 2005, 62:1167-1175. 10.1007/s00018-005-5050-2, 15928809.
220. Huang Q, Shen HM, Shui G, Wenk MR, Ong CN. Emodin inhibits tumor cell adhesion through disruption of the membrane lipid Raft-associated integrin signaling pathway. Cancer Res 2006, 66:5807-5815. 10.1158/0008-5472.CAN-06-0077, 16740720.
221. Wang XJ, Yang J, Cang H, Zou YQ, Yi J. Gene expression alteration during redox-dependent enhancement of arsenic cytotoxicity by emodin in HeLa cells. Cell Res 2005, 15:511-522. 10.1038/sj.cr.7290321, 16045814.
222. Cai J, Niu X, Chen Y, Hu Q, Shi G, Wu H, Wang J, Yi J. Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia 2008, 10:41-51. 10.1593/neo.07754, 2213898, 18231637.
223. Huang XZ, Wang J, Huang C, Chen YY, Shi GY, Hu QS, Yi J. Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther 2008, 7:468-475. 10.4161/cbt.7.3.5457, 18285700.
224. Wang W, Sun YP, Huang XZ, He M, Chen YY, Shi GY, Li H, Yi J, Wang J. Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation. Biochem Pharmacol 2010, 79:1134-1140. 10.1016/j.bcp.2009.12.006, 20005210.
225. Chen RS, Jhan JY, Su YJ, Lee WT, Cheng CM, Ciou SC, Lin ST, Chuang SM, Ko JC, Lin YW. Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Exp Cell Res 2009, 315:2658-2672. 10.1016/j.yexcr.2009.06.002, 19505457.
226. Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW. Emodin enhances cisplatin-induced cytotoxicity via down- regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer 2010, 69:155-164. 10.1016/j.lungcan.2009.10.013, 19962780.
227. Yue PY, Wong DY, Wu PK, Leung PY, Mak NK, Yeung HW, Liu L, Cai Z, Jiang ZH, Fan TP, Wong RN. The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem Pharmacol 2006, 72:437-445. 10.1016/j.bcp.2006.04.034, 16793023.
228. Liu TG, Huang Y, Cui DD, Huang XB, Mao SH, Ji LL, Song HB, Yi C. Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice. BMC Cancer 2009, 9:250. 10.1186/1471-2407-9-250, 2721848, 19624862.
229. Kim SM, Lee SY, Yuk DY, Moon DC, Choi SS, Kim Y, Han SB, Oh KW, Hong JT. Inhibition of NF-kappaB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Arch Pharm Res 2009, 32:755-765. 10.1007/s12272-009-1515-4, 19471891.
230. Kim SM, Lee SY, Cho JS, Son SM, Choi SS, Yun YP, Yoo HS, Yoon do Y, Oh KW, Han SB, Hong JT. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol 2010, 631:1-9. 10.1016/j.ejphar.2009.12.018, 20056115.
231. Kim HS, Lee EH, Ko SR, Choi KJ, Park JH, Im DS. Effects of ginsenosides Rg3 and Rh2 on the proliferation of prostate cancer cells. Arch Pharm Res 2004, 27:429-435. 10.1007/BF02980085, 15180309.
232. He BC, Gao JL, Luo X, Luo J, Shen J, Wang L, Zhou Q, Wang YT, Luu HH, Haydon RC, Wang CZ, Du W, Yuan CS, He TC, Zhang BQ. Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/ß-catenin signaling. Int J Oncol 2011, 38:437-445.
233. Luo X, Wang CZ, Chen J, Song WX, Luo J, Tang N, He BC, Kang Q, Wang Y, Du W, He TC, Yuan CS. Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human colorectal cancer cells. Int J Oncol 2008, 32:975-983. 2677725, 18425323.
234. Lee SY, Kim GT, Roh SH, Song JS, Kim HJ, Hong SS, Kwon SW, Park JH. Proteomic analysis of the anti-cancer effect of 20S-ginsenoside Rg3 in human colon cancer cell lines. Biosci Biotechnol Biochem 2009, 73:811-816. 10.1271/bbb.80637, 19352032.
235. Xu TM, Cui MH, Xin Y, Gu LP, Jiang X, Su MM, Wang DD, Wang WJ. Inhibitory effect of ginsenoside Rg3 on ovarian cancer metastasis. Chin Med J (Engl) 2008, 121:1394-1397.
236. Zhang Q, Kang X, Zhao W. Antiangiogenic effect of low-dose cyclophosphamide combined with ginsenoside Rg3 on Lewis lung carcinoma. Biochem Biophys Res Commun 2006, 342:824-828. 10.1016/j.bbrc.2006.02.044, 16499874.